Zhejiang Gongdong Medical Technology Co. Ltd. Class A

Zhejiang Gongdong Medical Technology Co. Ltd. Class A

SSSE:605369
16.76
CNY
-0.43
(-2.50%)
0.26EPS
66.65P/E
3.87BMarket Cap
Apr 27Next Earn
Zhejiang Gongdong Medical Technology Co. Ltd. Class A
SSE:605369
(Shanghai Stock Exchange)

Recent

price

16.76

P/E

ratio

66.65

div

yld

2.73%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.25
2.63
2.94
3.35
4.67
5.43
6.69
4.4
5.07
5.07
5.39
Revenue per Share
0.37
0.27
0.52
0.69
1.27
1.41
1.48
0.49
0.78
0.23
0.26
Basic EPS, GAAP
0.46
0.45
0.41
0.12
0.75
0.44
0.5
0.29
0.46
0.64
- -
Free Cash Flow per Basic Share
0.15
0.4
- -
0.31
- -
0.65
0.71
0.41
0.37
0.29
0.46
Dividend per Share
1.14
1.53
2.07
2.46
5.5
6.29
7.21
7.42
7.74
7.66
7.71
Book Value per Share
0.89
1.29
1.83
1.95
5.13
5.92
6.85
6.05
6.13
6.21
6.31
Tangible Book Value per Share
165
164
164
165
178
220
220
221
220
224
217
Basic Weighted Avg Shares
371
431
483
553
830
1,194
1,469
975
1,115
1,136
1,171
Sales/Revenue/Turnover
19.08
13.6
19.93
24.18
33.36
28.85
23.1
11.91
14.53
9.97
11.05
Operating Margin (%)
12
11
13
16
19
22
41
84
94
100
- -
Depreciation Expense
61
44
85
114
226
311
326
109
172
52
57
Net Income, GAAP
14.06
21.29
13.69
13.92
13.92
13.79
12.04
8.47
9.13
18.23
22.34
Effective Tax Rate (%)
16.3
10.26
17.6
20.54
27.23
26.04
22.2
11.19
15.39
4.54
4.88
Profit Margin (%)
77
140
206
154
884
840
871
637
682
699
718
Working Capital
- -
- -
- -
- -
- -
- -
- -
31
39
25
16
LT Debt
188
253
341
405
1,208
1,388
1,592
1,639
1,718
1,706
1,717
Total Equity
- -
17.57
25.8
29.07
27.71
23.61
21.94
6.73
10.15
2.95
3.02
Return on Invested Capital (%)
- -
17.93
26.45
29.02
28
23.95
21.87
6.76
10.13
3.09
3.15
Return on Capital (%)
- -
20.09
28.6
30.43
28
23.96
21.88
6.76
10.26
3.03
3.33
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
140
220
220
LT Borrowings
- -
- -
- -
LT Finance Leases
25
21
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
220
220
220
Market Capitalization
4,114
3,830
3,867

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,079
1,147
1,138
Cash, Cash Equivalents & STI
625
702
705
Accounts Receivable, Net
278
294
274
Inventories
138
118
130
Total Current Liabilities
380
420
419
Payables & Accruals
- -
- -
- -
ST Debt
140
220
220
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
7.34%
-0.66%
Free Cash Flow
- -
8.74%
41.26%
Net Income, GAAP
- -
-7.34%
-69.99%
Sales/Revenue/Turnover
- -
9.91%
1.84%
Total Cash Common Dividend
- -
- -
-19.14%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
272
282
282
279
1,115
2025
264
292
- -
291
1,136
2026
289
299
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.21
0.23
0.21
0.14
0.78
2025
0.12
0.1
- -
-0.09
0.23
2026
0.15
0.1
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.22
0.37
2025
- -
0.29
- -
- -
0.29
2026
0.01
0.16
- -
- -
- -
Business
Zhejiang Gongdong Medical Technology Co., Ltd. specializes in the manufacturing and sale of disposable medical and laboratory consumables, including vacuum blood collection tubes, specimen containers, petri dishes, vaginal speculums, swabs, centrifugation tubes, colorimetric cups, and cell culture products. Founded in 1985 and headquartered in Huangyan, Taizhou, China, the company operates one of the largest production facilities conforming to GMP standards, equipped with advanced injection and blow molding machinery. It primarily serves medical institutions and laboratories across China and internationally, exporting products to markets such as the United States. Recently, the company completed the acquisition of the remaining stake in Urumqi Jindongsheng Trading Co., Ltd. in January 2025, strengthening its distribution capabilities. Zhejiang Gongdong maintains a robust portfolio of over 500 product types across three major categories and holds multiple invention and utility model patents. It continues expanding through technological innovation, new product launches, and reinforcing global partnerships, while maintaining ISO 13485 and CE certifications to ensure quality and compliance in its medical device offerings. The company reported increased sales in medical testing and blood collection products for the fiscal year 2024, supporting its leadership position in the disposable medical plastic ware industry in China. Zhejiang Gongdong also emphasizes quality control and efficient production processes to maintain high standards across its expansive product range. This description reflects its core products, geographic reach, founding background, and recent major operational development of acquiring full ownership of a trading subsidiary to enhance market presence and distribution.